The small-cap biotech highlighted in today’s article has had mixed clinical results when it comes to one of its novel cancer immunotherapy candidates. The author, however, advises that “Despite the uncertainty surrounding [the candidate], investors shouldn’t be dismayed. Usually, when investing in small-cap biotech stocks, what’s far more important in the decision-making process is to see whether the company is backed by institutional investors” – and not only does this firm have institutional backing, but it also has a number of research and development partnerships with big pharma players. For more on this stock that may appeal to biotech investors with a high risk tolerance – CLICK HERE.
Why This Biotech’s Mixed Clinical Results Shouldn’t Discourage Investors With A High Risk Tolerance
Tags:Big Pharma PlayersBiotech InvestorsBiotech StocksInvestInvestinginvestorsSmall-Cap Biotech StocksSmall-Cap Biotechsstock market